COMPOSITION FOR TREATING METASTATIC SOLID CANCER, COMPRISING TSG6 INHIBITOR

• Main Authors: JANG, Hay-Ran, SHIN, Sol-Bi, YIM, Hyung Shin
• Format: Patent
• Language: English; French; Korean
• Published: 23.12.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to a use of TSG6 shRNA as a therapeutic agent for metastatic solid cancer. More specifically, the present invention can be usefully used for treating cancer in which metastasis occurs by PLK1, which is known to be overexpressed, especially in cancer, and the active form thereof or TGF-beta/Smad signaling, by reducing proliferation, migration, and invasiveness of metastatic cancer cells through gene therapy that inhibits TSG6 mRNA expression. La présente invention concerne l'utilisation de pARN TSG6 en tant qu'agent thérapeutique pour un cancer solide métastatique. Plus spécifiquement, la présente invention peut être utilisée de façon utile pour traiter un cancer dans lequel des métastases se produisent par PLK1, qui est connue pour être surexprimée, en particulier dans un cancer, et la forme active de celle-ci ou la signalisation de TGF-bêta/Smad, par réduction de la prolifération, de la migration et de l'invasivité de cellules cancéreuses métastatiques par thérapie génique qui inhibe l'expression d'ARNm de TSG6. 본 발명은 TSG6 shRNA의 전이성 고형암 치료제 용도에 관한 것으로, 보다 상세하게는, 본 발명은 TSG6 mRNA 발현을 억제하는 유전자 치료를 통해 전이성 암세포의 증식, 이동성 및 침습성을 감소시킴으로써 특히 암에서 과발현되는 것으로 알려진 PLK1과 그 활성형 또는 TGF-beta/Smad 신호전달에 의하여 전이가 일어나는 암의 치료에 유용하게 사용될 수 있다.